AbbVie stock costs EUR 248.30, 1.97 percent below its high

Published on 10/13/2026 at 16:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AbbVie reports third-quarter results on October 30, 2026. AbbVie stock costs EUR 248.30 on October 13, 2026, down 0.88 percent versus the Xetra close.

Updated earnings and trading levels

AbbVie stock was 1.97 percent below its 52-week high on October 13, 2026.
AbbVie reduced adjusted diluted earnings per share guidance to USD 13.76-13.96 for fiscal 2026 on October 5, 2026.
AbbVie stock costs EUR 248.30 at Lang & Schwarz on October 13, 2026 at 4:10 p.m. CEST, 0.88 percent below the Xetra close of October 12, 2026.
AbbVie is scheduled to report third-quarter 2026 results on October 30, 2026.

Fotorealistisches Pharma-Forschungslabor mit Petrischalen und Wissenschaftlern in Schutzkleidung — AbbVie Inc. US00287Y1091 fotorealistisches Pharma Forschungslabor mit Petrischalen Wissenschaftlern Immunologie Onkologie Biopharma, Illustration mit AI erstellt.

AbbVie stock costs EUR 248.30 at Lang & Schwarz on October 13, 2026 at 4:10 p.m. CEST, 1.97 percent below its 52-week high of EUR 253.30. The price is 0.88 percent below the Xetra close of EUR 250.50 from October 12, 2026.

Adjusted earnings guidance is lower

On October 5, 2026, AbbVie said adjusted diluted earnings per share guidance for fiscal 2026 was USD 13.76-13.96, down by USD 0.11 at both ends after acquired in-process research and development and milestone expenses of USD 216.00 million. The same expense is expected to reduce third-quarter adjusted diluted earnings per share guidance to USD 3.73-3.77, according to SEC.

The guidance change gives the October reporting date a specific benchmark. The upper end of the full-year range is USD 13.96, while the lower end is USD 13.76, a USD 0.20 span that includes the identified one-off expense.

Stock remains near its yearly high

AbbVie's 52-week range in the Xetra quotation is EUR 162.85 to EUR 253.30 as of October 13, 2026. At EUR 248.30, the stock is EUR 5.00 below the high, while the day's Lang & Schwarz volume was 313 shares against an average of 567 shares.

The price position is narrower than the annual range suggests. The current euro quotation is EUR 85.45 above the 52-week low and EUR 5.00 below the high, so the high-end position is the more relevant reference for the October report.

Valuation and reporting date

AbbVie had a market capitalization of EUR 442.6 billion and a price-to-earnings ratio of 79.18 on October 13, 2026, based on the Xetra quotation. The company is scheduled to announce third-quarter 2026 financial results before the US market opens on October 30, 2026, according to The Wall Street Journal.

Comparison with peers

AbbVie Inc.: minus 0.88 percent, price-to-earnings ratio 79.18, market capitalization EUR 442.6 billion.

Amgen (NASDAQ, USD): minus 0.09 percent, price-to-earnings ratio 25.94, market capitalization USD 225.2 billion.

Johnson & Johnson (NYSE, USD): minus 4.72 percent, price-to-earnings ratio 29.11, market capitalization USD 605.6 billion.

Price stays below the yearly high

AbbVie stock was trading at EUR 248.30 at Lang & Schwarz on October 13, 2026 at 4:10 p.m. CEST, 0.88 percent below the Xetra close of October 12, 2026 at EUR 250.50. The EUR 253.30 52-week high was 1.97 percent above the current price.

The further course of trading is shown by the continuously updated real-time quote of AbbVie stock.